Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination

被引:0
|
作者
Petrelli, Fiorella [1 ]
Giannini, Daiana [1 ]
Pucci, Celestino [1 ]
Del Corso, Isabella [1 ]
Rocchi, Valeria [1 ]
Dolcher, Maria Pia [1 ]
Pieve, Giulio [2 ]
Pratesi, Federico [1 ]
Migliorini, Paola [1 ]
Puxeddu, Ilaria [1 ]
机构
[1] Pisa Univ, Dept Clin & Expt Med, Immunoallergol Unit, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Direz Med Presidio, Pisa, Italy
关键词
COVID-19; Vaccine; Allergy; Skin test; Polyethylene glycol; Polysorbates; BNT162B2;
D O I
10.1159/000526764
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Introduction: Immediate and delayed hypersensitivity reactions (HSR) to COVID-19 vaccines are rare adverse events that need to be prevented, diagnosed, and managed in order to guarantee adherence to the vaccination campaign. The aims of our study were to stratify the risk of HSR to COVID-19 vaccines and propose alternative strategies to complete the vaccination. Methods: 1,640 subjects were screened for vaccinal eligibility, according to national and international recommendations. Among them, we enrolled for allergy workup 152 subjects, 43 with HSR to COVID-19 vaccines and 109 at high risk of HSR to the first dose. In vivo skin tests with drugs and/or vaccines containing PEG/polysorbates were performed in all of them, using skin prick test and, when negative, intradermal tests. In a subgroup of patients resulted negative to the in vivo skin tests, the programmed dose of COVID-19 vaccine (Pfizer/BioNTech) was administered in graded doses regimen, and detection of neutralizing anti-spike antibodies was performed in these patients after 4 weeks from the vaccination, using the SPIA method. Results: Skin tests for PEG/polysorbates resulted positive in only 3% (5/152) of patients, including 2 with previous HSR to COVID-19 vaccines and 3 at high risk of HSR to the first dose. Among the 147 patients with negative skin tests, 97% (143/147) were eligible for vaccination and 87% (124/143) of them received safely the programmed COVID-19 vaccine dose. Administration of graded doses of Pfizer/BioNTech vaccine were well tolerated in 17 out of 18 patients evaluated; only 1 developed an HSR during the vaccination, less severe than the previous one, and all developed neutralizing anti-spike antibodies after 4 weeks with values comparable to those subjects who received the vaccine in unfractionated dose. Conclusion: On the whole, the usefulness of the skin tests for PEG/polysorbates seems limited in the diagnosis of HSR to COVID-19 vaccines. Graded doses regimen (Pfizer/BioNTech) is a safe and effective alternative strategy to complete the vaccinal course.
引用
收藏
页码:54 / 62
页数:9
相关论文
共 50 条
  • [21] COVID-19 underreporting and its impact on vaccination strategies
    Albani, Vinicius
    Loria, Jennifer
    Massad, Eduardo
    Zubelli, Jorge
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [22] Procedure in case of allergy to COVID-19 vaccination
    Kempe, Sabrina
    ALLERGO JOURNAL, 2022, 31 (05) : 12 - 12
  • [23] Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia
    Novak, Natalija
    Tordesillas, Leticia
    Cabanillas, Beatriz
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2022, 41 (04) : 438 - 447
  • [24] Phenotypic distribution and tolerability of re-vaccination in individuals with delayed hypersensitivity to COVID-19 vaccines
    De Luca, Joseph
    Awad, Andrew
    Vogrin, Sara
    Waldron, Jamie
    Douglas, Abby
    Chua, Kyra
    Holmes, Natasha
    Trubiano, Jason
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB56 - AB56
  • [25] The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19
    Yildiz, Yesim
    Ozger, Hasan Selcuk
    Acar, Ali
    Seremet-Keskin, Aysegul
    Binay, Umut Devrim
    Unlu, Gulten
    Bayram, Halim
    Asan, Ali
    Akca, Mustafa Ozgur
    Karamanlioglu, Dilek
    Inan, Osman
    Kaya, Safak
    Yildirim, Cigdem
    Arslan, Yusuf
    Komur, Suheyla
    Saygideger, Yasemin
    Kandemir, Fatma Ozlem
    Yasar, Simge
    Akdemir-Kalkan, Irem
    Tekin-Tas, Zeynep
    Sakiz, Ayse
    Bayindir, Yasar
    Ozer, Ayse Belin
    Mete, Ayse Ozlem
    Erol, Cigdem
    Mermutluoglu, Cigdem
    Kadiroglu, Ali Kemal
    Azap, Alpay
    Senol, Esin
    INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2023, 5 (02): : 118 - 126
  • [26] Eosinophilic pneumonia following Sinovac/CoronaVac vaccination Comment on "Hypersensitivity reactions to COVID-19 vaccines: a case of eosinophilic pneumonia following Sinovac/CoronaVac vaccination "
    Sookaromdee, P.
    Wiwanitkit, V.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 55 (01) : 1 - 1
  • [27] COVID-19 and Its Impact on Common Diseases in the Allergy Clinics
    Kocatuerk, Emek
    Abrams, Elissa M.
    Maurer, Marcus
    Mitri, Jad
    Oppenheimer, John
    Vestergaard, Christian
    Zein, Joe
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (11): : 3289 - 3303
  • [28] Rare Hypersensitivity Myocardial Reactions Following COVID-19 Vaccination: Hypersensitivity Myocardial Infarction (Kounis Syndrome) and Hypersensitivity Myocarditis
    Kounis, Nicholas G.
    Koniari, Ioanna
    Mplani, Virginia
    Kouni, Sophia
    Velissaris, Dimitrios
    Plotas, Panagiotis
    Tsigkas, Grigorios
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2022, 26 (03): : 245 - 246
  • [29] Cutaneous Reactions of COVID-19 Infection and COVID-19 Vaccines - a Review
    Singal, Amit
    Desai, Amar D.
    Lipner, Shari R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB31 - AB31
  • [30] Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies
    Ulrichs, Timo
    Rolland, Morgane
    Wu, Jianhong
    Nunes, Marta C.
    El Guerche-Seblain, Clotilde
    Chit, Ayman
    EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 510 - 522